Clinical Trials Logo

Clinical Trial Summary

To compare the time to response, response rates, remission rates, and side effects in Bipolar Disorder inpatients treated with Depakote ER or Depakote DR for acute mania or mixed mania.


Clinical Trial Description

There are several studies demonstrating the efficacy of divalproex in the acute treatment of mania and mixed mania. In fact, the American Psychiatric Associations Practice Guidelines for Bipolar Disorder recommends divalproex as a first-line treatment for acute mania and acute mixed mania; divalproex is the treatment of choice in the treatment of acute mixed mania. The Food and Drug Administration (FDA) approved divalproex for the acute treatment of mania in the 1990's. A new formulation, divalproex, Depakote ER, was recently FDA approved for the treatment of epilepsy and prophylaxis of migraine headaches. In a pooled data analysis of nine open-labeled trials involving 321 epilepsy and bipolar disorder patients, Smith et al. that Depakote ER was associated with superior tolerability including less frequent tremors, weight gain, and gastrointestinal complaints (all p<0.001) compared with Depakote DR. Depakote ER was preferred by subjects and it provided improved seizure control and a greater reduction in psychiatric symptoms. ;


Study Design

Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00334347
Study type Interventional
Source Massachusetts General Hospital
Contact
Status Completed
Phase Phase 4
Start date June 2006
Completion date September 2007

See also
  Status Clinical Trial Phase
Recruiting NCT05206747 - Ottawa Sunglasses at Night for Mania Study N/A
Completed NCT00534222 - Unraveling the Relation of Patient's Profile and Therapeutical Effects of Atypicals, Including Quetiapine Effect N/A
Completed NCT00140179 - Valnoctamide in Mania Phase 3
Completed NCT01237379 - Peroxisomal Defects and Familial Risk for Bipolar Disorder N/A
Completed NCT01315028 - Bipolar Intervention Study: Cognitive Interpersonal Therapy N/A
Completed NCT00254488 - Treatment of Bipolar Mania in Older Adults Phase 4
Completed NCT00560079 - Efficacy of Allopurinol and Dypiridamole in Acute Mania Phase 4
Completed NCT00518947 - Pharmacotherapy of Treatment-Resistant Mania Phase 3
Recruiting NCT05444907 - Deep Brain Stimulation-Induced Mania in Parkinson's Disease
Enrolling by invitation NCT02360267 - Pediatric Bipolar Registry
Completed NCT01092221 - Allopurinol for Mania: A Randomized Trial Administering Allopurinol vs. Placebo as add-on to Mood Stabilizers and/or Antipsychotics in Patients in a Bipolar Manic Episode Phase 3
Completed NCT00521365 - Effectiveness of Quetiapine XR on the Control of Symptoms of Manic Phase of Bipolar Disorder. Phase 4
Completed NCT01191918 - The Efficacy and Safety of AChE Inhibitor Donepezil As Adjunctive Treatment to Mood Stabilizers in Acute Mania Phase 4
Completed NCT01541605 - Methylphenidate for the Treatment of Acute Mania Phase 3
Completed NCT00893581 - Multimodal Neuroimaging of Treatment Effects in Adolescent Mania N/A
Completed NCT00208195 - Depakote ER Therapy for Mania Comorbid With Substance Abuse Phase 4
Completed NCT00181922 - Ziprasidone for the Treatment of Mania in Children and Adolescents With Bipolar Disorder Phase 4
Completed NCT00181935 - Risperidone Versus Olanzapine for Mania in Preschool Children 4 to 6 Years of Age With Bipolar Disorder Phase 4
Active, not recruiting NCT05703711 - Combining mHealth and Nurse-delivered Care to Improve the Outcomes of People With Serious Mental Illness in West Africa N/A
Completed NCT00917501 - Neurochemical Effects of Omega-3 Fatty Acids in Adolescents at Risk for Mania Phase 2